FDA advisers back Medtronic deep brain stimulator for Parkinson's symptoms
This article was originally published in Clinica
An advisory panel to the US FDA has recommended that Medtronic's Activa deep brain stimulator system be approved for treating the symptoms of Parkinson's disease. The device has been on the market in the US for three years and elsewhere in the world for at least two, for treating essential tremor but US FDA advisers on March 31 still argued at length whether they should give their backing to expanded use of the technology.
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
Breakthrough solutions based on new biological entities (ADCs and mAbs) are making hope real for patients with conditions of high unmet medical need. Byondis is developing therapies that target intractable cancers and autoimmune diseases and taking precision medicine to the next level.